Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes | Zendy

Kieren J. Mather | Zendy; Robert V. Considine | Zendy; LaTonya Hamilton | Zendy; Niral A. Patel | Zendy; Carla J. Mathias | Zendy; Wendy Territo | Zendy; Adam G. Goodwill | Zendy; Johnathan D. Tune | Zendy; Mark Green | Zendy; Gary D. Hutchins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes

Author(s) -

Kieren J. Mather,

Robert V. Considine,

LaTonya Hamilton,

Niral A. Patel,

Carla J. Mathias,

Wendy Territo,

Adam G. Goodwill,

Johnathan D. Tune,

Mark Green,

Gary D. Hutchins

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-00712

Subject(s) - liraglutide , insulin detemir , medicine , metformin , insulin , type 2 diabetes , endocrinology , diabetes mellitus , context (archaeology) , gastroenterology , insulin glargine , biology , paleontology

It is unclear if effects of glucagon-like peptide-1 (GLP-1) and clinically available GLP-1 agonists on the heart occur at clinical doses in humans, possibly contributing to reduced cardiovascular disease risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research